Yahoo Finance • last year
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments a... Full story
Yahoo Finance • last year
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day... Full story
Yahoo Finance • last year
NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented... Full story
Yahoo Finance • last year
Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif., July 06, 2023 (GLO... Full story
Yahoo Finance • 2 years ago
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing... Full story
Yahoo Finance • 2 years ago
LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that Dr. Denise Scots-Knight... Full story
Yahoo Finance • 2 years ago
LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that Dr. Denise Scots-Knight... Full story
Yahoo Finance • 2 years ago
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that on November 1, 2022, i... Full story
Yahoo Finance • 2 years ago
Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024 Annual General Meeting of Shareholders L... Full story
Yahoo Finance • 2 years ago
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D upd... Full story
Yahoo Finance • 2 years ago
Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value Details Rubric’s Rejection of Reasonable Settlement Proposals... Full story
Yahoo Finance • 2 years ago
Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones Reiterates Commitment to Disciplined Capital Allocation and Management of Mereo’s... Full story
Yahoo Finance • 2 years ago
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the development and commercialization of novel... Full story
Yahoo Finance • 2 years ago
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions Announces Further Extension of Cash Runway into Q2 2025 LONDON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma... Full story
Yahoo Finance • 2 years ago
Mereo BioPharma Group plc LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and on... Full story
Yahoo Finance • 2 years ago
Yahoo Finance Live takes a look at several of today's trending stocks tied to leading industry stories, including the demand destruction seen in energy markets as rising gas prices have more people opting to work from home than commuting.... Full story
Yahoo Finance • 2 years ago
--ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patients with Stable Disease as of April 2022 data cut off-- --Etigilimab safe and well tolerated, no new safety signals-- --Prioritization initiatives extend cash runw... Full story
Yahoo Finance • 2 years ago
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases of Stable Diseases (SD) as of the February 10, 2022... Full story
Yahoo Finance • 3 years ago
LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the... Full story
Yahoo Finance • 3 years ago
Mereo BioPharma Group plc Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant redu... Full story